VivoLab AB’s Post

The Alliance for Artificial Intelligence in Healthcare (AAIH) is excited to partner with BioTechX for their BioTechX EU and BioTechX USA events this year 🤝   ➡ BioTechX EU is Europe’s largest congress covering diagnostics, precision medicine and digital transformation in pharmaceutical development and healthcare. The congress features senior speakers from the top 50 pharmaceutical companies, biotechs, healthcare systems and academic groups creating endless networking opportunities.   ➡ BioTechX USA covers diagnostics, precision medicine and digital transformation in pharmaceutical development and healthcare. Now running for the second year, they are bringing conversations to the East Coast and hope to both maintain and foster new relations with key stakeholders in the healthcare industry.   📍 In 2024 (9 - 10 October) BioTechX EU will return to Basel, the pharma hub of Europe, this time with 3500 global executives, 400 speakers and 50 start-ups all under one roof.   📍BioTechX US is a 2-day event taking place on the 17th and 18th of September 2024 in Pennsylvania, a thriving hub of innovation. Aiming to bring 1500 global executives, 300 speakers and 50 start-ups.     🎟 BioTechX EU: AAIH members and guests who work in pharma, academia, or health systems can apply for a free ticket using this link: https://lnkd.in/dkDnYMNc   🎟 BioTechX US: AAIH members and guests who work in pharma, academia, or health systems can apply for a free ticket using this link: https://lnkd.in/dxJBWkDu   🎟 If you are a product or service provider, a consultant, or working in tech, use this exclusive AAIH discount code for 50% off a 2-Day Standard Package at both BioTechX USA and EU: AAIH50   #biotechx #congress  #healthcare #pharma #networking #diagnostics #precisionmedicine

Milin Shah, Gilead Sciences, will moderate a panel session on Alternative Approaches to High-Volume/High-Concentration Injectable Delivery at the upcoming #PODD2023 conference. More specifically, panelists will discuss: ▪️ Different ways to overcome volume challenges from formulation and device perspectives ▪️ Challenges of characterization, immune response, local site reactions, and the technologies to overcome, slow or minimize those reactions ▪️ Upper limits of high-volume delivery and barriers to navigate Learn more about the upcoming conference here - https://lnkd.in/fZPZNbb #DrugDelivery #PartnershipOpportunities #Formulation #PODD2023 Pfizer Bristol Myers Squibb EdgeOne Medical Kaléo

Pharma need biotech's innovation to fuel future pipeline success and safeguard revenues that are increasingly coming under pressure from pricing and patent cliffs. Biotech need pharma's infrastructure, commercialisation knowledge and of course access to investment to support the ongoing development of pioneering science. Nowhere is that mutually beneficial, yet competitive, dynamic more acute then in ADCs and targeted radiopharmaceuticals... ...that is why we've launched the inaugural ADC & Radiopharmaceutical Pharma & Biotech Partnering Summit in Boston to unite S&E, BD&L and partnering professionals from pharma, C-level execs from Biotech and the wider investment community who are 100% focused and aligned on translating the next generation of safe, effective and differentiated ADCs and TRPs through the clinic and to patients in need. You got to check it out! https://ter.li/ipq457

WHEN WILL CLINICAL DEVELOPMENT COSTS BE ADDRESSED ..WHEN UNLIMITED US PRICING OF DRUGS CEASES Everything about the costs in the pharmaceutical industry is opaque, that is fully intentional. Everyone takes overpriced advantage in an "honor among thieves" fashion with "the sucker," i.e. taxpayers/insurance premium payers footing the bill for this monopoly. Global Pharma's US predatory pricing model is ending, costs of drug development will come fully under the microscope and the type of quantitative price modeling and project cost management that this emerging company (Strategikon Pharma) offers will become essential. #pharma #pharmaceuticals #clinicaldevelopment #clinicaltrials #drugpricing #strategikonpharma AREhttps://lnkd.in/ewastvjR

🔍 Shaping pharma's future: Maximizing returns through strategic investment 💡 Explore the reality of diminishing returns in pharmaceutical R&D through Frank Kumli's latest article. Learn about the challenges and practical solutions reshaping drug development. 🌐 Digital healthcare technologies may hold the key to increasing pipeline efficiencies, and a new breed of start-ups looks set to revolutionize the sector, provided they can attract the attention of suitable investors. 🌐 Healthtech hubs, such as the Novartis Campus in Basel, Switzerland, offer these fledgling companies an environment alongside pharmaceutical giants and other innovative corporations, fostering a collaborative culture to drive drug development into the 21st century. 🔗 Don't miss this exploration into the future of #healthtech. Read the insights to discover practical keys to innovation in the pharmaceutical industry. 🔗 https://lnkd.in/dByChJkS Ursula Costa, 👉 Cécile Tardy-Srinivasan, Florian Saner, Yana Yoncheva, Anca del Rio, MSPH, Pascal Clisson, Rahel Schneider, Caoimhe Vallely-Gilroy #WhyBaselArea #MoreToDiscover #DrugDevelopment #digitalhealth

I am in agreement with Anca Copaescu about the need to take a long hard look at how we are approaching clinical development, and this article is well worth a read. With the pressures on drug pricing around the world and the spiralling development costs we need a seismic shift in our approaches in all areas. I'll leave comments on the application of technology to the experts 😉👍🏻 but a massive amount should be done in the design and planning stage of a trial. In addition to the scientific and medical considerations, early inclusion of relevant historic data (both pricing and delivery), alongside operational considerations and outsourcing options is vital to enable: 1️⃣ Improved stakeholder management 2️⃣ Informed and timely decision making 3️⃣ Expedited vendor selection and contracting 4️⃣ More realistic scope and pricing 5️⃣ Greater clarity of responsibilities in contracts 6️⃣ Fewer change orders & better overall performance 7️⃣ Higher CRO accountability for delivery In my experience, all too often, insufficient consideration is given to the operational feasibility and resourcing/outsourcing strategies compared to the protocol design. As a result we defer problems and issues until much later in the study, with a commensurate increase in resolution time and cost implications (dare I mention the 1:10:100 rule again?!?! 🤦🏻♂️😏) Incorporating the right technology solutions is important, but must be done alongside a thorough review of current working practices in order to maximise the benefits and gain a true competitive advantage. The R&D Outsourcing Advisory group of 4C Life Sciences has extensive experience, skills and knowledge, alongside compliant tools and processes to help clients plan for success, identify and explain their needs, and avoid unnecessary issues throughout the life of the study. Feel free to reach out if you have a question or challenge you'd like help with.

Collaboration is key for pioneering medical advancement It is the collaboration between companies, research and knowledge institutions, and government in Rotterdam that is the breeding ground for many medical innovations that originate here and find their way to patients all over the world. This is also the opinion of Desiree van der Kleij, Chief Operating Officer of Cerba Research. "Ultimately, creating economic value goes hand in hand with improving healthcare and quality of life." @Cerba Research exemplifies this collaborative spirit. By supporting clinical and preclinical studies for the development of drugs and vaccines, they contribute significantly to improving global health. Their advanced diagnostics and expert guidance empower the biopharmaceutical sector to develop next-generation treatments for viral infections. Cerba Research receives these clients in the Rotterdam Science Tower, where it carries out clinical trials for large pharmaceutical companies in a four-story laboratory. A pleasant environment, according to Van der Kleij. "It is a building with a high wow-factor. You walk in and you are not only overwhelmed by the view of the Rotterdam skyline, but we also form an inspiring community that gives ambitious entrepreneurs the place to grow." Learn more about the Rotterdam Science Cluster: https://lnkd.in/ewb7GpUb #Rotterdam #Genomics #LifeSciences #Collaboration #Innovation

🌟 Exciting Announcement! New for 2024 🌟 Join us at the highly anticipated Prefilled Syringes East Coast 2024 for our enlightening Roundtable Discussion Sessions! Whether you're involved in device development, drug delivery, these sessions are crafted to enhance knowledge and spark collaborations. Roundtable Discussions Include: 🔹 Roundtable 1: Effective device lifecycle management strategies from early R&D to commercial launch Primary Perspective: Ning Yu, Executive Director, Astria Therapeutics, Inc. Commercial Perspective: Terry O’Hagan, General Manager, Haselmeier™ A medmix Brand 🔹 Roundtable 2: Successfully integrating combination product development with wider drug product development Primary Perspective: Michael Song, Director, Moderna Commercial Perspective: John Merhige, CEO, CREDENCE MEDSYSTEMS, INC. 🔹 Roundtable 3: Designing the next generation of combination products meeting needs of merging drug products via material choices and more Primary Perspective: Theresa Scheuble, Head of Design & Innovation, Johnson & Johnson Commercial Perspective: Charlie Dean, Head of Sustainable Medical Technology, Cambridge Consultants Don’t miss the chance to engage with industry leaders and peers in a dynamic setting, exploring groundbreaking strategies and the future of prefilled syringes and combination products. Secure one of the last remaining tickets here > https://ow.ly/n92750RiUrU

Pharma's #digitalhealth investments are being clawed back and innovation hubs restructured. Approaches to #HealthTech are shifting and #MedTech could be the new path forward. Register here https://lnkd.in/eQnbTPWb to join pharma and MedTech experts from Roche, Novo Nordisk, Merck Group, Novartis and ViiV Healthcare as we carve out pharma's future in the MedTech space.

Yesterday AstraZeneca announced the launch of Evinova, a #healthtech business that takes the work that we have been doing at AstraZeneca Digital Health R&D to transform the speed, reach and effectiveness with which life changing therapies can be brought to patients - and commits to scaling it up to support transformation not only within AstraZeneca, but also across the life sciences sector. I feel very fortunate to be part of this - not only because of scale of the ambition, but because this is an important step in the maturing collaboration between #humancentereddesign and the #lifesciences. The collaboration between human-centred design and computer-science that transformed the tech industries matured quite a while ago, having been getting its act together since the 1970's. Human-centred design and the life sciences started getting it together much more recently. AstraZeneca's commitment to the launch of a science-based, evidence-led and human-experience driven health-tech business represents a significant new chapter in that story.